Clinical trials: Alzheimer's
Alzheimer's Disease
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00021723
- Testing
- AN-1792 also known as AIP-001
- Where
- 11 sites in United States
- Volunteers
- 375 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Mild Cognitive Impairment
Glymphatic Function TMS Study
The purpose of this study is to use transcranial magnetic stimulation (TMS) in older adults to impact the glymphatic system. The glymphatic system is a brain-wide clearance pathway that plays a crucial role in removing…
- Trial name
- GF-TMS (NCT07192913)
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Alzheimer's Disease
Control and Intervention Programme on Alzheimer's Disease Risk Factors
Recent epidemiologic studies are identifying a number of modifiable risk and protective factors that may influence in the incidence of Alzheimer's disease (AD).
- Trial name
- ALFAlife (NCT02772523)
- Testing
- Lifestyle recommendations
- Where
- Spain
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Cognition Disorders
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
The LEARN study a multicenter, observational study will that will evaluate the rate of cognitive change in approximately 500 clinically normal older individuals who "screen-fail" for the A4 trial on the basis of their screening…
- Trial name
- LEARN (NCT02488720)
- Where
- 40 sites in United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Memory Disorders
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.
- Trial name
- IMASMART (NCT05709210)
- Testing
- Recording of smartphone usage data
- Where
- France
- Volunteers
- 71 people
- Sponsor
- Poitiers University Hospital
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Alzheimer Disease, Dementia
Tablet-based Cognitive Training
Today the therapy options for dementia due to Alzheimer's disease (AD) are limited. One recommended intervention is cognitive stimulation.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT04452864
- Testing
- Computerized Cognitive Training, Documentaries with delayed Computerized Cognitive Training
- Where
- 2 sites in Switzerland
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- University of Bern
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Down Syndrome (DS)
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
The aim of the study is to determine the safety and tolerability of different increasing doses of MIB-626 (a microcrystalline form of β nicotinamide mononucleotide; NMN) given daily for 28 consecutive days to adults with Down…
- Trial name
- NCT07278492
- Testing
- MIB-626
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Brigham and Women's Hospital
Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04464564
- Testing
- AVP-786
- Where
- 106 sites in United States, Belgium and 11 more
- Volunteers
- 241 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Caregiver Burden, Anxiety
Caring Relationships Expression Study
This study will examine a heart rate variability biofeedback (HRVB) intervention versus a music listening control (MLC) for 30 family caregivers (FCGs) of Alzheimer's disease (AD) (and related dementias: ADRD) patients to examine…
- Conditions
- Caregiver Burden, Anxiety, Stress
- Trial name
- CARES (NCT05627687)
- Testing
- Heart Rate Variability Biofeedback, Music Listening Control
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Memory Disorders, Alzheimer's Disease
Amyloid Plaque and Tangle Imaging in Aging and Dementia
Amyloid senile plaques (SPs) and neurofibrillary tangles (NFTs) are neuropathological hallmarks of Alzheimer's disease (AD) that also accumulate in key brain regions in association with normal aging.
- Trial name
- NCT00355498
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Mild Cognitive Impairment, Alzheimer Disease
Music Therapy for Patients With Alzheimer's Disease
This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or…
- Trial name
- NCT05151562
- Testing
- Virtual Music Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Alzheimer's Disease
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
The primary purpose of this study is to determine if the study medication Methylphenidate (Ritalin) will improve subject's blood-sugar control by improving their motivation more than placebo.
- Conditions
- Diabetes Mellitus, Alzheimer's Disease, Apathy, Dementia
- Trial name
- NCT00792662
- Testing
- Methylphenidate
- Sponsor
- University of Nebraska
Physical Therapy
Trunk Control, Balance, Gait, Functional Mobility and Fear of Falling in People With Alzheimer's Disease
The purposes of this study were to investigate the relationship between trunk control and balance, gait, functional mobility, and fear of falling in people with Alzheimer's disease and to compare trunk control, balance, gait…
- Trial name
- NCT05576688
- Testing
- Balance, Trunk control, Gait
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease
Agitation in Alzheimer's Disease
Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness.
- Trial name
- NCT00000179
- Testing
- Trazodone, Haloperidol
- Where
- 16 sites in United States
- Sponsor
- National Institute on Aging (NIA)